secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001178913-25-002390
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics announces 1-for-15 reverse share split to maintain Nasdaq listing
--------------------------------------------------------------------------------

- Reverse split effective after market close July 28; split-adjusted trading starts July 29 under ticker SLXN.
- Every 15 ordinary shares combined into 1; fractional shares rounded up to nearest whole share.
- Par value increases from $0.0009 to $0.0135 per share; no action required from shareholders.
- Split designed to regain compliance with Nasdaq minimum bid price rule (Listing Rule 5550(a)(2)).
- CEO Ilan Hadar states split supports strategic growth initiatives and capital markets positioning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002390/0001178913-25-002390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002390/zk2533447.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-002390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer